Clinical Trials Sponsored by Ironwood Pharmaceuticals, Inc

Total 4950 results

Ironwood Pharmaceuticals, Inc.

Completed

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

Healthy

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

United States, Canada
Ironwood Pharmaceuticals, Inc.

Terminated

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Dyspepsia | Functional Gastrointestinal Disorders

Belgium, Netherlands
Ironwood Pharmaceuticals, Inc.

Completed

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation

Constipation

United States
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.

Recruiting

Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis | Bladder Pain Syndrome

United States
Ironwood Pharmaceuticals, Inc.

Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

Canada, United States
Ironwood Pharmaceuticals, Inc.

Completed

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

Diabetic Gastroparesis

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Completed

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Gastroesophageal Reflux

United States
Ironwood Pharmaceuticals, Inc.

Completed

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Chronic Constipation

United States
Ironwood Pharmaceuticals, Inc.

Completed

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

Hypercholesterolemia

United States
Allergan
Ironwood Pharmaceuticals, Inc.

Completed

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Functional Constipation

United States
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
AbbVie
Ironwood Pharmaceuticals, Inc.

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Functional Constipation

United States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
AbbVie
Ironwood Pharmaceuticals, Inc.

Recruiting

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Functional Constipation (FC) | Chronic Idiopathic Constipation (CIC)

United States, United Kingdom, Bulgaria, Netherlands
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
Ironwood Pharmaceuticals, Inc.
Medpace, Inc.

Terminated

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Gout | Chronic Kidney Disease (CKD)

United States, Hungary, Poland, Czechia
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Constipation

Chronic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Opioid-Induced Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Functional Constipation in Children Ages 6-17 Years

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
University of Nottingham
Ironwood Pharmaceuticals, Inc.

Completed

Ispaghula and Colonic Water Content

Healthy

United Kingdom
University of Nottingham
Ironwood Pharmaceuticals, Inc.

Completed

MRI and Microbiota Analysis in Constipation (MIMIC)

Constipation

United Kingdom
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea (IBS-D)

United States
Ironwood Pharmaceuticals, Inc.
Manchester University NHS Foundation Trust

Terminated

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United Kingdom
Mayo Clinic
AbbVie; Cedars-Sinai Medical Center; Ironwood Pharmaceuticals, Inc.

Not yet recruiting

A Study of Virtual Reality and Linaclotide for IBS-C (IBSC-VR)

Irritable Bowel Syndrome With Constipation

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States

Clinical Trials Sponsored by Ironwood Pharmaceuticals, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations